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OBJECTIVES We sought to test the efficacy of a passive elastic containment device to reverse chronic
chamber remodeling and adrenergic down-regulation in the failing heart, yet still maintaining
preload reserve.
BACKGROUND Progressive cardiac remodeling due to heart failure is thought to exacerbate underlying
myocardial dysfunction. In a pressure–volume analysis, we tested the impact of limiting
progressive cardiac dilation by an externally applied passive containment device on both basal
and adrenergic-stimulated function in failing canine hearts.
METHODS Ischemic dilated cardiomyopathy was induced by repeated intracoronary microembolizations
in six dogs. The animals were studied before and three to six months after surgical
implantation of a thin polyester mesh (cardiac support device [CSD]) that surrounded both
cardiac ventricles. Pressure–volume relations were measured by a conductance micromanom-
eter catheter.
RESULTS Long-term use of the CSD lowered end-diastolic and end-systolic volumes by19 4% and
22  8%, respectively (both p  0.0001) and shifted the end-systolic pressure–volume
relation to the left (p  0.01), compatible with reverse remodeling. End-diastolic pressure
and chamber diastolic stiffness did not significantly change. The systolic response to
dobutamine markedly improved after CSD implantation (55  8% rise in ejection fraction
after CSD vs. 10  8% before CSD, p  0.05), in conjunction with a heightened adenylyl
cyclase response to isoproterenol. There was no change in the density or affinity of
beta-adrenergic receptors. Diastolic compliance was not adversely affected, and preload-
recruitable function was preserved with the CSD, consistent with a lack of constriction.
CONCLUSIONS Reverse remodeling with reduced systolic wall stress and improved adrenergic signaling can
be achieved by passive external support that does not generate diastolic constriction. This
approach may prove useful in the treatment of chronic heart failure. (J Am Coll Cardiol
2002;39:2069–76) © 2002 by the American College of Cardiology Foundation
Chronic cardiac remodeling is a major hallmark of dilated
cardiomyopathy and is thought to play a central role in
disease progression (1–4). Chamber dilation and wall thin-
ning elevate wall stress, triggering the local release of
neurohormones and adversely affecting myocardial molecu-
lar biology and physiology (3). Both beta-adrenergic block-
ade and angiotensin-converting enzyme inhibition enhance
heart failure survival and inhibit or reverse remodeling
(5–8). Further evidence supporting a pathophysiologic role
of remodeling stems from studies of left ventricular assist
devices (LVADs). This intervention profoundly unloads the
left heart, leading to reverse remodeling (9,10) and improv-
ing myocyte and muscle function (11,12), molecular and
calcium signaling (11,13,14) and adrenergic responsiveness
(15). However, LVAD studies cannot determine the ther-
apeutic effect of limiting chronic remodeling on the working
heart, nor can they easily differentiate unloading influences
from changes due to systolic assist and neurohormonal
de-activation.
The impact of limiting remodeling on heart failure
progression has been directly tested by the application of
external containment. An example of this approach is
cardiomyoplasty (16,17), in which a flat sheet of skeletal
muscle is wrapped around the heart and then stimulated to
assist systolic contraction. Intriguingly, both clinical (18)
and animal studies (19) have identified a passive girdling
effect of the wrap as a dominant mechanism responsible for
reverse remodeling and improved function. Such observa-
tions have led to the development of a passive polymer
jacket that surrounds the heart (cardiac support device
[CSD]; Acorn Cardiovascular Inc., St. Paul, Minnesota). In
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recent studies, the CSD has been shown to limit progressive
dilation in heart failure (20), enhance fractional shortening
and reduce myocyte hypertrophy and interstitial fibrosis
(21,22). However, it remains unknown whether this reflects
true remodeling or an influence of diastolic constraint, and
whether the CSD favorably alters stimulated functional
reserve.
Accordingly, the present study tested the following hy-
potheses: 1) that the CSD induces reverse remodeling, as
reflected by a leftward shift in the end-systolic pressure–
volume relation (ESPVR); 2) that this is accompanied by
enhanced beta-adrenergic signaling; and 3) that both effects
are achieved without limiting preload-recruitable reserve or
compromising diastolic compliance.
METHODS
Animal model. Heart failure was induced in six adult
mongrel dogs (25 to 30 kg) by multiple sequential intra-
coronary embolizations with polystyrene latex microspheres
(70 to 100 m outer diameter). This model includes many
features of human cardiac failure at the chamber, myocar-
dial, cellular and molecular levels (23–25). An average of six
microembolizations were performed one to three weeks
apart in each animal, until the ejection fraction declined to
35%, a level associated with a 20% to 30% increase in
chamber volume. The procedure was performed under
sterile conditions and general anesthesia (see next para-
graph), and the study approved by the Henry Ford Hospi-
tal’s Animal Care and Use Committee, in accordance with
the guidelines of the National Institutes of Health.
Experimental protocol. After establishing heart failure,
the animals underwent cardiac catheterization with a dual-
sensor, pressure–volume catheter (SPC 562 Millar Instru-
ments, Houston, Texas) to assess ventricular function.
Right and left heart recordings and a contrast ventriculo-
gram were obtained under general anesthesia (0.22 mg/kg
oxymorphone; 0.17 mg/kg diazepam; 150 to 250 mg pen-
tobarbital). Left ventricular pressure–volume relations were
then measured at rest and during a transient preload
reduction induced by inferior vena caval occlusion (NuMed,
New York, New York), in accordance with reported proto-
cols (26). Each animal subsequently underwent dobutamine
challenge (5 to 10 g/kg per min), with data recorded at
steady-state. Dobutamine was then discontinued and base-
line was re-established (after 10 to 15 min), and then the
dogs were given four sequential bolus injections of 100 ml of
dextran to test for preload reserve. All catheters were then
removed, and the insertion sites were closed.
The CSD was implanted after completion of the baseline
study. Details of the surgical procedure have been reported
(20,21,27). After induction with diazepam (0.2 mg/kg
intravenously) and oxymorphone (0.1 mg/kg), the animals
were intubated, and anesthesia was maintained with 0.5% to
1% isoflurane and supplemental oxygen. The heart was
exposed by a median sternotomy, and the parachute tech-
nique was used to implant the CSD, by slipping it over the
apex of the heart with the full-length seam at the center of
the anterior surface. The CSD was placed around both
ventricles and anchored with approximately eight sutures at
the atrioventricular groove (Fig. 1). The fit was made so that
the material was nonwrinkled, thus providing contact with
the epicardium throughout the cycle. There was only a
small, early volume change with CSD placement (2.1%),
as determined by echocardiography. The chest was closed,
and the animals fully recovered from the operation. Once in
use, the CSD becomes encased in a thin fibrous sheath
without inflammation or progressive fibrosis (21).
Follow-up study was performed three to six months after
CSD implantation. The dogs were then sacrificed with a
barbiturate overdose, and tissues were obtained for bio-
chemical analyses.
Adenylyl cyclase activity. Frozen left ventricular (LV)
tissue (300 to 400 mg) was thawed in 5 mmol/l Tris (pH
7.4), 0.25 mol/l sucrose, 1 mmol/l MgCl2, 1 mmol/l EDTA
Figure 1. The cardiac support device wrap placed around the heart. The
polyester mesh material is sutured along an anterior wall seam to achieve
containment around both the right and left ventricles. The material is snug
to the surface to remove surface wrinkling, but not to constrict diastolic
filling.
Abbreviations and Acronyms
ATP  adenosine triphosphate
cAMP  cyclic adenosine monophosphate
CSD  cardiac support device
DHA  3H-dihydroalprenelol
ESPVR  end-systolic pressure–volume relation
LV  left ventricle
LVAD  left ventricular assist device
PMSF  phenylmethylsulfonyl fluoride
RV  right ventricle
SDS  sodium dodecyl sulfate
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and 10 mol/l phenylmethylsulfonyl fluoride (PMSF) and
homogenized for 45 s. The homogenates were filtered and
centrifuged at 1,000 g (10 min, 4°C); the supernatant was
recovered and centrifuged at 45,000 g (25 min, 4°C); and
the pellets were resuspended in 25 ml of 50 mmol/l Tris
(pH 7.4), 10 mmol/l MgCl2, 1 mmol/l EDTA and
10 mol/l PMSF and centrifuged at 45,000 g (25 min,
4°C). After rewashing in the same solution, the pellet was
resuspended in 0.5 ml of buffer and analyzed immediately.
Triplicate samples were incubated for 10 min at 37°C and
contained the indicated effector, along with 10 to 20 g of
membrane protein: 25 mmol/l Tris (pH 7.5), 5 mmol/l
MgCl2, 0.5 mmol/l EDTA, 1 mmol/l cyclic adenosine
monophosphate (cAMP), 1 mmol/l adenosine triphosphate
(ATP), [-32P]ATP (0.5 to 1.5 Ci/tube, 800 Ci/mmol),
5 mol/l PMSF, 7 mmol/l creatine phosphate, 50 n/ml
creatine kinase and 0.25 mg/ml bovine serum albumin in a
final volume of 100 l. Adenylyl cyclase activity was
measured under basal conditions, with 10 mol/l guanosine
triphosphate (GTP) plus 1 nmol/l to 100 mol/l isoproter-
enol or 10 mol/l forskolin. The reactions were terminated
by the addition of 100 l of buffer: 50 mmol/l HEPES (pH
7.5), 2 mmol/l ATP, 0.5 mmol/l cAMP, 2% sodium
dodecyl sulfate (SDS) and 1 Ci/ml 3H-cAMP (37 Ci/
mmol). Newly synthesized 32P-cAMP was separated from
the precursor [-32P]ATP by sequential column chroma-
tography with Dowex and aluminum oxide, using recovery
of 3H-cAMP to monitor the individual column’s efficiency.
Eluted radioactivity was quantitated by liquid scintillation.
Beta-adrenergic receptor radioligand binding. Beta-
adrenreceptor density was measured using radioligand 3H-
dihydroalprenelol (DHA) (New England Nuclear, Boston,
Massachusetts), according to published procedures (28).
Specific binding to the beta-adrenoceptor population was
defined as the difference between the total amount of
radioactivity bound in the presence of 3H-DHA alone and
the nonspecific binding in the presence of 3H-DHA and
10 mol/l alprenolol. Receptor density (Bmax) and the
equilibrium dissociation constant (Kd) for
3H-DHA bind-
ing to membrane preparations were assessed by Scatchard
analysis, using the ReceptorFit Saturation Two-Site Soft-
ware (Lundon Software, Inc., Cleveland Heights, Ohio).
Data analysis. Pressure–dimension data were recorded at
steady-state and during inferior vena caval occlusion; the
latter was used to derive pressure–volume relations. Details
of the hemodynamic analysis have been reported (29).
Systolic function was principally indexed by the ESPVR and
preload-recruitable stroke work (30). Preload was expressed
as the end-diastolic volume, and arterial load as the effective
arterial elastance. The volume signal was calibrated to match
the absolute ventricular volumes obtained by constrast
ventriculography. All hemodynamic signals were digitally
recorded at 200 Hz and analyzed using custom software.
Hemodynamic variables before and after CSD implantation
were compared by the Student paired t test. The differ-
ential effects of dobutamine stimulation before versus
after CSD placement were analyzed by three-way analysis
of variance (ANOVA), with drug, experimental condi-
Figure 2. Hemodynamic effects of the cardiac support device (CSD). (A) Left ventricular pressure–volume relations in one animal before and after
long-term CSD use. The darker loops for each condition reflect basal conditions, and the thinner loops were measured during transient load reduction.
There was a reduction in both end-diastolic and end-systolic chamber volumes, with preservation of cardiac stroke volume (loop width), and the end-systolic
pressure–volume relation shifted leftward, consistent with reversal of chamber remodeling. The diastolic pressure–volume boundary was not altered. (B)
Summary of hemodynamic variables before and after long-term CSD use. There was a consistent significant decline in chamber volumes (end-diastolic
volume [EDV] and end-systolic volume [ESV]), without a change in cardiac output (CO). End-diastolic pressure (EDP) and end-systolic pressure (ESP)
were not significantly changed. EF  ejection fraction.
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tion and dog as the categorical variables. A different
dobutamine response was defined by significance of the
cross-term (dobutamine  condition). Adenylate cyclase
data were analyzed by two-way ANOVA. Data are reported as
the mean value  SEM.
RESULTS
Induction of reverse remodeling in the heart by use of the
CSD. Figure 2A displays examples of pressure–volume
loops and relations before and after long-term CSD treat-
ment. Placement of the CSD resulted in a leftward shift in
the rest pressure–volume loop (thicker lines), as well as in
the ESPVR. The latter observation is consistent with
reversal of remodeling. In contrast, the diastolic pressure–
volume curve was changed only a little. The leftward
ESPVR shift was quantified by the end-systolic volume at a
matched end-systolic pressure measured in the physio-
logic range (110 mm Hg, or V110). The V110 fell from
44.7  5.2 to 33.9  3.9 ml by long-term CSD treatment
(p  0.01). In contrast, the ESPVR slope was not
significantly altered (2.5  0.59 before CSD vs. 4.3  2.3
after CSD, p  NS).
The diastolic pressure–volume relation was more variably
affected, with some animals displaying a leftward shift and
others a downward shift, whereas others had no change.
Diastolic chamber elastic stiffness (), as determined from a
monoexponential fit (P  P  [e
V  1]) did not signif-
icantly change (0.09  0.03 before CSD vs. 0.11 
0.02 ml1 after CSD, p  0.4).
Figure 2B provides a summary of the hemodynamic data.
Both end-systolic and end-diastolic volumes significantly
declined by 22.1  7.6 and 18.7  4.2%, respectively
(both p  0.0001). In contrast, the EF, end-systolic
pressure, end-diastolic pressure, cardiac output (Fig. 2B),
maximal rate of rise in pressure (2,025  130 vs. 1,765 
67 mm Hg/s), isovolumic relaxation (49.9  4.5 vs. 51.7 
5.4 ms, using a non-zero decay asymptote) and preload-
recruitable stroke work (54.1 11.1 vs. 54.4 9.4 mm Hg)
were not altered. It should be noted that LV end-diastolic
pressure either declined or remained minimally changed.
Consistent with previous reports (21), we found no evidence
of functional constraint after CSD implantation. Right and
left heart diastolic pressures were not equalized (19 3 mm
Hg for LV end-diastolic pressure; 8  1 mm Hg for right
ventricular [RV] end-diastolic pressure) after long-term
CSD use.
Preload-recruitable systolic reserve. Because the CSD
imposed an external containment around the heart, one
Figure 3. Effects of an early preload increase in the failing heart after cardiac support device (CSD) implantation. (A) Example of pressure–volume relations
before and after infusion of 400 ml of dextran. (B) Summary of hemodyanmic variables in relation to incremental volume expansion. For a near 10 mm
Hg rise in end-diastolic pressure (EDP), cardiac output (CO) rose by nearly 100%, and there were significant changes in both the maximal and minimal
rates of pressure change. Thus, preload-dependent reserve function was not inhibited by CSD placement. dP/dtmx and dP/dtmn  rate of rise in left
ventricular pressure, maximal and minimal, respectively. *p  0.05 versus baseline, e.g. 0 volume expansion.
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concern was that the observed reverse remodeling would be
accompanied by inhibition of cardiac preload reserve. Ad-
ministering dextran infusions in the CSD-treated animals
tested this hypothesis. As shown in Figure 3, the preload
increased the end-diastolic pressure, as anticipated, but this
was accompanied by substantial increases in systolic perfor-
mance. There was no square-root sign in LV pressure–time
tracings (Fig. 3A, bottom graph) before or after volume
infusion, supporting the lack of constrictive physiology.
Cardiac output rose nearly 100%, and both the maximal rates
of rise and decline in pressure were significantly enhanced.
Improved beta-adrenergic reserve and the CSD. Figure 4
shows an example of and summary data on beta-adrenergic
reserve before and after CSD placement. In the basal heart
failure state, early dobutamine infusion elicited a small
systolic response, although this was considerably enhanced
after long-term CSD treatment. Stroke volume, stroke
work, ejection fraction and cardiac output initially tended to
decline with dobutamine, yet each variable rose significantly
with the same dobutamine dose after CSD placement (all
p  0.01 for interaction effect of dobutamine and CSD
status by ANOVA).
To further assess the mechanism(s) of the augmented
adrenergic response with long-term CSD treatment, LV
myocardial isoproterenol-stimulated adenylate cyclase activ-
ity was determined. This response was enhanced (Fig. 5A)
in CSD-treated animals, as compared with a parallel group
of animals (n  5) with heart failure induced by the same
methods and for a similar duration, but without CSD place-
ment. In contrast, adenylate cyclase activity in response to
forskolin was similar between the groups (Fig. 5B), supporting
signaling changes proximal to the enzyme itself. Neither the
beta-adrenergic receptor density (76  4 vs. 81  5 fmol/mg
with the CSD) nor the binding affinity (1.31  0.1 vs. 1.3 
0.1 nmol/l) was different between the two groups.
DISCUSSION
This study provides direct evidence that application of a
purely passive external containment to a chronically failing
Figure 4. Enhancement of the dobutamine (Dob) response with long-term cardiac support device (CSD) treatment. (A) Example of pressure–volume loops
and relations during early dobutamine infusion stimulation at baseline and after long-term CSD treatment. The pre-dobutamine end-systolic
pressure–volume relation (ESVPR) (control) is shown for baseline and CSD treatment. Before CSD placement, the dobutamine response was very small,
with only a slight leftward shift in the ESPVR. However, the magnitude of the response to this same dose was greatly augmented by long-term CSD
treatment. (B) Percent changes in systolic function in response to dobutamine, comparing baseline with CSD treatment. Substantial increases were observed
in response to multiple ejection variables: CO  cardiac output; EF  ejection fraction; SV  stroke volume; SW  stroke work; power index  maximal
power/end-diastolic volume (EDV)2. *p  0.001 and †p  0.02 compared with baseline response, by three-way analysis of variance of raw data.
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heart leads to reversal of chamber remodeling, as detected by
a leftward ESPVR shift and accompanied by augmented
post-receptor sensitivity and responsiveness to beta-
adrenergic stimulation. The CSD effect could not be attrib-
uted to systolic assistance and, importantly, was achieved in
an intact working heart, without causing diastolic constric-
tion that would otherwise inhibit preload reserve.
Reversing remodeling: unloading versus contain-
ment. Cessation or reversal of progressive chamber remod-
eling is an important aim of heart failure therapy (1,3,4,31).
Successful pharmacologic approaches have targeted neuro-
hormones, supporting the link between remodeling and
angiotensin and catecholamine toxicity. Recent surgical
approaches provide a more direct test of the importance of
chamber load and structural geometry of the failing heart.
The LVAD has been the most widely studied approach, and
it can dramatically unload the LV, leading to reverse
remodeling (9,32,33). At the cellular level, this results in
reversal of many heart failure abnormalities involving gene
expression (12,13,34), calcium homeostasis (13,35), hyper-
trophy (12), energetics (14) and adrenergic signaling (15).
This demonstrates remarkable plasticity of the failing heart
in response to profound cardiac unloading and systolic
assistance. However, such data do not identify an effect of
limiting dilation/remodeling, per se, as LVADs also restore
cardiac output and markedly reduce neurohormonal activa-
tion. Recent comparisons between RV and LV myocardial
responses support a load effect from the LVAD (36), but
this analysis remains indirect, as RV failure varies among
patients, and synergistic influences of neurohormonal deac-
tivation and normalized output on unloading cannot be
ruled out.
External containment, such as that provided by the CSD,
physically limits cardiac expansion and, in so doing, breaks
a positive feedback loop by which progressive dilation and
dysfunction are coupled. This strategy of external contain-
ment differs from interventions that directly remodel the
heart by removing myocardium (37,38) or placing stents to
alter its shape and regional load (39). Hints that contain-
ment alone might lead to reverse remodeling first came from
studies of cardiomyoplasty. Although this method com-
bined an effect of external girdling with systolic assistance
from skeletal muscle contraction, clinical data suggest that
the former mechanism was particularly potent (18). Passive
effects of the wrap were directly tested in an experimental
model, where asynchronous, nonburst stimulation was ap-
plied to maintain skeletal muscle health, yet not elicit a
contraction (19). Intriguingly, reverse remodeling and im-
proved function by this approach were nearly identical to
those seen when tetanic systolic cardiomyopathy stimulation
was also applied (40), further supporting the notion that
containment was a primary mechanism.
The CSD was developed as an artificial material alterna-
tive to a passive skeletal muscle wrap. Early reports per-
formed in an ovine model of heart failure induced by rapid
pacing found that the CSD limited progressive heart dila-
tion and mitral regurgitation (20). Similar effects were then
demonstrated in an ischemic cardiomyopathic model in
association with diminished myocyte hypertrophy and fi-
brosis (21). The present results expand these findings in
several major ways. The pressure–volume analysis identified
reverse remodeling in the absence of constrictive pathophys-
iology as hallmarks of the CSD effect. The observed
leftward shift in the ESPVR, with little net slope change, is
Figure 5. (A) Isoproterenol-stimulated adenylate cyclase activity in the failing myocardium, with or without cardiac support device (CSD) treatment. The
CSD resulted in an enhanced dose response to isoproterenol. The p value is for the CSD effect on the dose response, by two-way analysis of variance.
(B) Adenylyl cyclase activity with direct activation by forskolin revealed no difference between the groups, suggesting altered up-stream signaling as the
major source for the disparity in part A. CHF  chronic heart failure.
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very similar to those experimental and clinical results with
cardiomyoplasty (18,41). Also, in concordance with cardio-
myoplasty, the CSD did not have a significant net effect on
diastolic compliance, although it prevented progressive di-
lation.
The present data employing the CSD should be com-
pared with time-controlled data from the same model of
ischemic dilated cardiomyopathy, but without this device.
As previously reported, animals in this latter model display
progressive cardiac dilation and a reduced ejection fraction
(21)—strikingly different from the results with the CSD.
The observation that a purely passive wrap that does not
quickly shrink the size of the heart can eventually lead to
reverse remodeling is very intriguing. Although the exact
mechanism remains unclear, one hypothesis is that the
failing heart involves multiple interactive pathways with
concomitant changes that can be both adverse and poten-
tially ameliorative. Unchecked, the balance favors adverse
factors and results in gradual deterioration. However, simply
by limiting one of these important factors—that is, chamber
remodeling—the CSD may tip the balance to allow favor-
able signaling pathways and energy utilization to become
effective, and thereby help reverse progressive failure and
enhance adrenergic signaling.
Improved adrenergic response. Improved beta-adrenergic
signaling observed with the CSD is similar to that reported
with LVAD therapy (15). With the CSD, this change
occurred despite continued left heart loading and work, and
without direct systolic assistance that could reduce the tonic
adrenergic tone. Furthermore, the effects were obtained in
hearts that were not terminally depressed. Unlike the
LVAD, however, there was no change in beta-receptor
density (or affinity) with the CSD, despite augmented
adenylate cyclase responses to receptor stimulation and
functional changes in the whole heart. This may reflect
differences between the CSD and LVAD, which is associ-
ated with more extreme LV unloading and concomitant
systemic changes. The precise mechanism for an enhanced
beta-adrenergic response with the CSD remains unknown,
but may lie in alterations in beta-adrenergic receptor kinase,
G-protein signaling or cyclic guanosine monophosphate
metabolism and catabolism.
Containment versus constriction. The major concern re-
garding external containment devices is whether or not they
constrict diastolic filling and, thereby, preload reserve. The
pericardium of the failing heart dilates to accommodate
myocardial enlargement, but this expansion is generally
insufficient to prevent limitations of preload reserve (42).
The passive properties of the CSD are less abruptly non-
linear, compared with the pericardium, with a pressure rise
of 7 mm Hg for 20% volume expansion, and a rise of 9
mm Hg at 30% expansion. This better enables the material
to stretch to accommodate the filling volume. We found
that long-term CSD use allowed substantial systolic reserve
with early volume expansion. There was no equalization of
diastolic pressures between the right and left heart, nor an
LV pressure square-root sign characteristic of restrictive (or
constrictive) filling either before or after marked volume
loading. Recent clinical studies have found no evidence of
interference with coronary flow in either native or bypass
vessels in humans (43). The passive properties of the mature
CSD, with its fibrous in-growth, remain to be determined,
and this is likely to be somewhat stiffer than the CSD alone.
Nonetheless, the current data suggest that this combination
remains sufficiently pliable to accommodate early volume
expansion, yet still limit remodeling/expansion.
Study limitations. We did not perform pressure–volume
studies in a parallel sham-operated group, but we did repeat
studies in each animal. Previous historic control data in the
same experimental model have been reported and support
progressive dilation in the absence of the CSD. The
duration of CSD treatment was somewhat variable, partially
due to practical problems of having to transport co-
investigators and equipment from one city to another to
perform the studies. Nonetheless, we discerned no signifi-
cant differences due to this time disparity. Furthermore, the
magnitude of the initial volume change with CSD place-
ment was somewhat variable, partly due to the lack of
precise on-line measures of CSD snugness and volume
change.
Conclusions. We have shown that a purely passive external
elastic containment device can reverse remodeling in the
failing heart and improve beta-adrenergic signaling, while
preserving preload reserve. Preliminary clinical studies with
the CSD have been recently reported (27), and the approach
appears both safe and generally well tolerated. Ongoing
randomized clinical trials in the U.S. and Europe aim to
assess the efficacy of the CSD in limiting chronic remodel-
ing in human cardiomyopathy. Such studies should provide
the first tests, in humans, of the hypothesis that limiting
remodeling alone in the intact working heart can improve
long-term function and provide a useful therapy for heart
failure.
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